Скачать или смотреть American Gene Technologies

David Pauza, Ph.D., Chief Science Officer
Rockville, MD
(Private)

American Gene Technologies (AGT), is an emerging genetic medicine company with a proprietary lentiviral platform capable of broad applications including large and orphan indications, immuno-oncology and monogenic disorders. AGT will enter the clinic in 2017 with a Phase I clinical trial to evaluate AGT103 as a functional cure for HIV. Pre-IND applications for phenylketonuria (PKU) and hepatocellular carcinoma (HCC) will follow. These therapies demonstrate the breadth of AGT’s unique lentiviral platform, including such innovations as a Transient Vector™ for temporary (non-integrating) lentiviral expression and an ImmunoTox™ vector for stimulating anti-tumor immune-response in immuno-oncology applications. AGT continues to strengthen its patent pipeline and IP protection that now contains 10 patent families providing multi-factored “picket fence” protection around key developments and technological innovations. AGT’s proprietary platform innovations enable rapid therapeutic discovery at a fraction of the cost of other methods and platforms. www.americangene.com